Cell Therapy Manufacturing– tag –
-
Ori Biotech Secures $120M, 10-Year Partnership for Automated Cell Therapy Manufacturing; Vyriad’s In Vivo CAR-T Clears IND
RegMedNet UK Overview Ori Biotech announced a 10-year, $120 million partnership with an undisclosed biopharma firm to automate cell therapy manufacturing using its IRO platform, aiming to improve patient access. Concurrently, Vyriad secu... -
Typewriter Therapeutics Secures $56M Series A for In Vivo CAR-T, Aiming to Streamline Cell Therapy Manufacturing
BioBucks USA Overview Typewriter Therapeutics has raised $56 million in Series A funding to advance its innovative in vivo CAR-T cell therapy, designed to reprogram T cells directly within the patient's body. This approach eliminates the... -
Global Cell and Gene Therapy Manufacturing Services Market to Surge to $31.3 Billion by 2035, Driven by Regulatory Modernization
openPR.com (DataM Intelligence) Global Overview According to DataM Intelligence, the global cell and gene therapy manufacturing services market is projected to reach $8.77 billion in 2026, growing rapidly to $31.3 billion by 2035 with a ... -
Watchmaker Genomics Bolsters Global Supply Chain, Doubles Manufacturing Capacity with 100,000 Sq Ft Boulder Facility
Longmont Times-Call USA Overview Life sciences firm Watchmaker Genomics Inc. has significantly expanded its global manufacturing capabilities by securing approximately 100,000 square feet of new production space in Boulder, Colorado. Thi... -
Biotech Alliances Surge: Alteogen-Novartis Subcutaneous Drug Delivery Deal and NewBiologix-Synastra Gene Therapy Manufacturing Partnership Highlight Industry Trends
PharmExec Unknown Overview Alteogen has signed an option and license agreement with Novartis for subcutaneous drug development, while NewBiologix and Synastra announced a partnership to develop stable production cell lines for Duchenne m... -
Century Therapeutics Seeks Director to Lead Large-Scale Cell Therapy Process Development for Clinical and Commercial Programs
JobLeads (Century Therapeutics, Inc.) USA Overview Century Therapeutics is recruiting a Director of Large-Scale Process Development to lead scale-up strategies for bioreactor expansion, harvesting, and fill/finish operations in their cli... -
Cell and Gene Therapy Sector Shifts to “Execution Discipline” Amidst Manufacturing Platform Scrutiny and Autoimmune CAR-T Safety Concerns
LucidQuest Ventures USA Overview A recent strategic roundup highlights a critical shift in the cell and gene therapy (CGT) sector from platform expansion to "execution discipline," emphasized by Bristol Myers Squibb's termination of its ... -
Global Summits Confront Cell & Gene Therapy Scale-Up: Automation, Cost Efficiency, and Mass Production Strategies
Informa Connect International Overview Upcoming international conferences, including Advanced Therapies Europe and the CAR-TCR Summit in September 2026, are set to address the urgent need for scalable and cost-effective manufacturing in ... -
Bristol Myers Squibb Terminates $380M CAR-T Manufacturing Partnership with Cellares Due to Production Failures for Breyanzi
PharmaLive USA Overview Bristol Myers Squibb (BMS) has ended its $380 million partnership with Cellares, citing Cellares' Cell Shuttle system's failure to meet commercial production requirements for BMS's CAR T-cell immunotherapy, Breyan... -
Cellistic CTO Highlights Japanese Conditional Approvals for Cardiac and Parkinson’s iPSC Products, Outlining Path to Commercial-Scale iPSC Cell Therapy Manufacturing
The Medicine Maker UK Overview In an interview with The Medicine Maker, Stefan Braam, CTO of Cellistic, stated that the industry's main focus is the ability to consistently provide iPSC-based cell therapies at commercial scale for large ...
